No Data
When Will Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Become Profitable?
Craig-Hallum Maintains Xeris Pharmaceuticals(XERS.US) With Buy Rating, Announces Target Price $5
Sapiens International Posts Downbeat Results, Joins Sky Harbour And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Xeris Biopharma Price Target Maintained With a $3.00/Share by Piper Sandler
Xeris Biopharma Holdings Analyst Ratings
H.C. Wainwright Maintains Xeris Pharmaceuticals(XERS.US) With Buy Rating, Raises Target Price to $6.6
No Data
No Data